Skip to main content

ADVERTISEMENT

Giovanni Amoroso, MD, PhD

Original Contribution
10/15/2018
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12...
10/15/2018
Journal of Invasive Cardiology
Original Contribution
12/15/2015
An assessment of the safety and feasibility of “virtual 3 Fr” transradial percutaneous coronary intervention (TRA-PCI) in an outpatient setting.
An assessment of the safety and feasibility of “virtual 3 Fr” transradial percutaneous coronary intervention (TRA-PCI) in an outpatient setting.
An assessment of the safety and...
12/15/2015
Journal of Invasive Cardiology
Original Contribution
01/03/2022
The randomized REVELATION trial showed that in the setting of STEMI, a drug-coated balloon strategy was non-inferior to a drug-eluting stent strategy in terms of fractional flow reserve assessed at 9 months. The aim of the present study is to...
The randomized REVELATION trial showed that in the setting of STEMI, a drug-coated balloon strategy was non-inferior to a drug-eluting stent strategy in terms of fractional flow reserve assessed at 9 months. The aim of the present study is to...
The randomized REVELATION trial...
01/03/2022
Journal of Invasive Cardiology